The mechanism of action involves binding to and activation of melanocortin receptors, primarily the MC3 receptor subtype, which is a G-protein coupled receptor expressed in the hypothalamus and peripheral tissues. Receptor engagement triggers intracellular cAMP accumulation through Gαs protein coupling, leading to activation of downstream signaling pathways that modulate energy expenditure, appetite regulation, and metabolic processes. As the natural ligand for MC3R, this γ₂-MSH fragment exhibits specific receptor binding affinity and activates physiological responses involved in energy homeostasis, including regulation of food intake, energy balance, and cardiovascular function, without the need for structural modifications to enhance receptor interaction.

This γ₂-MSH fragment is indicated for research use only in preclinical studies investigating melanocortin receptor biology, energy metabolism, obesity and metabolic syndrome, appetite regulation, and cardiovascular physiology. It serves as a natural ligand in receptor binding assays, functional assays measuring cAMP production, and animal models of metabolic disorders. The product is used to study the physiological roles of MC3R in energy homeostasis, glucose metabolism, and cardiovascular regulation, as well as in comparative studies with modified analogs to understand structure-activity relationships. It is not intended for diagnostic, therapeutic, or clinical applications in humans or animals, and should be handled by trained research personnel in appropriate laboratory settings.

As a research reagent, γ₂-MSH (41-58), amide does not have established clinical efficacy for therapeutic use in human patients. While γ₂-MSH and related melanocortin peptides have been studied in preclinical models to understand their physiological roles in metabolic regulation, this specific peptide fragment has not undergone clinical development or received regulatory approval for any medical indication. Research using this peptide has contributed to the understanding of melanocortin signaling pathways and the identification of potential therapeutic targets for metabolic diseases, but the product remains an investigational research tool without proven clinical efficacy or safety profile for human use.